Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynaecology,Oncology
Reference24 articles.
1. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N. Engl. J. Med.,2011
2. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011
3. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design;Markman;J. Clin. Oncol.,2004
4. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer;Rauh-Hain;Int. J. Gynecol. Cancer,2013
5. Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP)±bevacizumab (BEV) for epithelial ovarian cancer (EOC);Birrer;J. Clin. Oncol.,2015
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Potential Influence of Residual or Recurrent Disease on Bevacizumab Treatment Efficacy in Ovarian Cancer: Current Evidence and Future Perspectives;Cancers;2024-03-05
2. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies;International Journal of Gynecologic Cancer;2024-03
3. Highlights from the 24th European Congress on Gynaecological Oncology in Istanbul: an ENYGO-IJGC Fellows compilation;International Journal of Gynecologic Cancer;2023-12-18
4. Surgery in Recurrent Ovarian Cancer: A Meta-Analysis;Cancers;2023-07-02
5. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study);International Journal of Clinical Oncology;2022-10-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3